title: Chemotherapeutic targeting of myeloid-derived suppressor cells.
abstract: Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.
authors.affiliation: Department of Pediatrics; Steele Children's Research Center; the University of Arizona Cancer Center; Tucson, AZ USA ; Cancer Biology Graduate Program; University of Arizona; Tucson, AZ USA.
authors.forename: Darya
authors.initials: D
authors.lastname: Alizadeh
authors.affiliation: Department of Pediatrics; Steele Children's Research Center; the University of Arizona Cancer Center; Tucson, AZ USA ; Cancer Biology Graduate Program; University of Arizona; Tucson, AZ USA ; Department of Immunobiology and BIO5 Institute; University of Arizona; Tucson, AZ USA.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Katsanis
authors.affiliation: Department of Pediatrics; Steele Children's Research Center; the University of Arizona Cancer Center; Tucson, AZ USA ; Cancer Biology Graduate Program; University of Arizona; Tucson, AZ USA ; Department of Immunobiology and BIO5 Institute; University of Arizona; Tucson, AZ USA.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Larmonier
keywords: ROS; cancer; chemoimmunomodulation; doxorubicin; helper T lymphocytes; myeloid-derived suppressor cells